Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$10.30 USD
-0.31 (-2.92%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $10.39 +0.09 (0.87%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.30 USD
-0.31 (-2.92%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $10.39 +0.09 (0.87%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.66% and 26.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 112.50% and 7.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
by Zacks Equity Research
Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.
GSK (GSK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 15.60% and 6.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.45% and 7.57%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -75% and 46.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 19.63% and 27.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Cidara (CDTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cidara (CDTX) stock based on the movements in the options market lately.
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Cidara Therapeutics (CDTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.
Cidara Therapeutics (CDTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 0.00% and 95.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.